{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:14:41Z","timestamp":1789719281741,"version":"4.0.1"},"reference-count":97,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Persistently enhanced platelet activation has been characterized in polycythemia vera (PV) and essential thrombocythemia (ET) and shown to contribute to a higher risk of both arterial and venous thrombotic complications. The incidence of major bleeding complications is also somewhat higher in PV and ET than in the general population. Although its efficacy and safety was assessed in just 1 relatively small trial in PV, low-dose aspirin is currently recommended in practically all PV and ET patients. Although for most patients with a thrombosis history the benefit\/risk profile of antiplatelet therapy is likely to be favorable, in those with no such history this balance will depend critically on the level of thrombotic and hemorrhagic risks of the individual patient. Recent evidence for a chemopreventive effect of low-dose aspirin may tilt the balance of benefits and harm in favor of using aspirin more broadly, but the potential for additional benefits needs regulatory scrutiny and novel treatment guidelines. A clear pharmacodynamic rationale and analytical tools are available for a personalized approach to antiplatelet therapy in ET, and an improved regimen of low-dose aspirin therapy should be tested in a properly sized randomized trial.<\/jats:p>","DOI":"10.1182\/blood-2012-10-429134","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T01:14:40Z","timestamp":1358558080000},"page":"1701-1711","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":85,"title":["Platelet activation and inhibition in polycythemia vera and essential thrombocythemia"],"prefix":"10.1182","volume":"121","author":[{"given":"Carlo","family":"Patrono","sequence":"first","affiliation":[{"name":"Department of Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Catholic University School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2019111809010126400_B1","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"2019111809010126400_B2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years.","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","journal-title":"Ann Intern Med"},{"issue":"10","key":"2019111809010126400_B3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"10","key":"2019111809010126400_B4","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111809010126400_B5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11739-009-0319-3","article-title":"Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.","volume":"5","author":"Vannucchi","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"3","key":"2019111809010126400_B6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ajh.23135","article-title":"Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.","volume":"87","author":"Tefferi","year":"2012","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111809010126400_B7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia.","volume":"74","author":"Rocca","year":"1995","journal-title":"Thromb Haemost"},{"issue":"8","key":"2019111809010126400_B8","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.","volume":"80","author":"Landolfi","year":"1992","journal-title":"Blood"},{"issue":"7","key":"2019111809010126400_B9","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood.V99.7.2612","article-title":"Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis.","volume":"99","author":"Viallard","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111809010126400_B10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.","volume":"84","author":"Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"issue":"24","key":"2019111809010126400_B11","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis.","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111809010126400_B12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0038-1645038","article-title":"Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina.","volume":"63","author":"Vejar","year":"1990","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111809010126400_B13","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/0735-1097(93)90312-O","article-title":"Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty.","volume":"21","author":"Ciabattoni","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2019111809010126400_B14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/01.STR.30.3.546","article-title":"Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage.","volume":"30","author":"van Kooten","year":"1999","journal-title":"Stroke"},{"issue":"2","key":"2019111809010126400_B15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2005.03.079","article-title":"Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.","volume":"47","author":"Santilli","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"2019111809010126400_B16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.288.16.2008","article-title":"Platelet activation in obese women: role of inflammation and oxidant stress.","volume":"288","author":"Dav\u00ec","year":"2002","journal-title":"JAMA"},{"issue":"11","key":"2019111809010126400_B17","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.ATV.17.11.3230","article-title":"In vivo formation of 8-Epi-prostaglandin F2 \u03b1 is increased in hypercholesterolemia.","volume":"17","author":"Dav\u00ec","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2019111809010126400_B18","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1172\/JCI116715","article-title":"Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.","volume":"92","author":"Di Minno","year":"1993","journal-title":"J Clin Invest"},{"issue":"4 pt 1","key":"2019111809010126400_B19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1164\/ajrccm.162.4.9911071","article-title":"In vivo lipid peroxidation and platelet activation in cystic fibrosis.","volume":"162","author":"Ciabattoni","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2019111809010126400_B20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1538-7836.2007.02387.x","article-title":"Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.","volume":"5","author":"Guthikonda","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111809010126400_B21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH08-03-0186","article-title":"Immature platelets in patients with acute coronary syndromes.","volume":"101","author":"Grove","year":"2009","journal-title":"Thromb Haemost"},{"issue":"3","key":"2019111809010126400_B22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0609.1995.tb00209.x","article-title":"Automated measurement of reticulated platelets in estimating thrombopoiesis.","volume":"54","author":"Watanabe","year":"1995","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019111809010126400_B23","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/j.thromres.2010.08.002","article-title":"Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis.","volume":"126","author":"Moles-Moreau","year":"2010","journal-title":"Thromb Res"},{"issue":"9","key":"2019111809010126400_B24","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2011-02-339655","article-title":"JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.","volume":"118","author":"Panova-Noeva","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111809010126400_B25","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target.","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111809010126400_B26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/09537100600758677","article-title":"Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.","volume":"17","author":"Michiels","year":"2006","journal-title":"Platelets"},{"issue":"1","key":"2019111809010126400_B27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"2019111809010126400_B28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2009.149","article-title":"Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.","volume":"6","author":"Tefferi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2019111809010126400_B29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2019111809010126400_B30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111809010126400_B31","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3","article-title":"Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients.","volume":"67","author":"Colombi","year":"1991","journal-title":"Cancer"},{"issue":"1","key":"2019111809010126400_B32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111809010126400_B33","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2019111809010126400_B34","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.","volume":"112","author":"Carobbio","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2019111809010126400_B35","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111809010126400_B36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111809010126400_B37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2141.2011.08858.x","article-title":"Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients.","volume":"156","author":"Palandri","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111809010126400_B38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0025-6196(12)60486-8","article-title":"Essential thrombocythemia in young adults.","volume":"66","author":"McIntyre","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2019111809010126400_B39","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low-risk thrombocythaemia: results from a prospective study.","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111809010126400_B40","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111809010126400_B41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis.","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111809010126400_B42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.beha.2012.06.007","article-title":"Venous thromboembolism: epidemiology and magnitude of the problem.","volume":"25","author":"Goldhaber","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2019111809010126400_B43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"9678","key":"2019111809010126400_B44","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"7553","key":"2019111809010126400_B45","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"issue":"21","key":"2019111809010126400_B46","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism.","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111809010126400_B47","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis.","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111809010126400_B48","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809010126400_B49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7326\/0003-4819-102-4-466","article-title":"Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.","volume":"102","author":"Michiels","year":"1985","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111809010126400_B50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","article-title":"Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.","volume":"97","author":"van Genderen","year":"1997","journal-title":"Br J Haematol"},{"issue":"17","key":"2019111809010126400_B51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111809010126400_B52","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.","volume":"23","author":"Tartaglia","year":"1986","journal-title":"Semin Hematol"},{"issue":"7","key":"2019111809010126400_B53","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111809010126400_B54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.2830490406","article-title":"Platelet von Willebrand factor abnormalities in myeloproliferative syndromes.","volume":"49","author":"Castaman","year":"1995","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111809010126400_B55","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V68.6.1213.1213","article-title":"Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome.","volume":"68","author":"Budde","year":"1986","journal-title":"Blood"},{"issue":"7","key":"2019111809010126400_B56","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","article-title":"Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111809010126400_B57","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets.","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111809010126400_B58","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin.","volume":"61","author":"Burch","year":"1978","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111809010126400_B59","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition.","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"issue":"8","key":"2019111809010126400_B60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance.\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"3-4","key":"2019111809010126400_B61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb Res"},{"issue":"6","key":"2019111809010126400_B62","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"issue":"7329","key":"2019111809010126400_B63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"25","key":"2019111809010126400_B64","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","article-title":"Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.","volume":"120","author":"Frelinger","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"2019111809010126400_B65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.bloodjournal691180","article-title":"Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"issue":"3","key":"2019111809010126400_B66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1161\/HYPERTENSIONAHA.111.181404","article-title":"Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.","volume":"59","author":"Smith","year":"2012","journal-title":"Hypertension"},{"issue":"2","key":"2019111809010126400_B67","first-page":"404","article-title":"Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).","volume":"102","author":"Blais","year":"2009","journal-title":"Thromb Haemost"},{"issue":"14","key":"2019111809010126400_B68","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.","volume":"28","author":"Lordkipanidz\u00e9","year":"2007","journal-title":"Eur Heart J"},{"issue":"15","key":"2019111809010126400_B69","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/hrt.2008.150631","article-title":"Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease.","volume":"95","author":"Muir","year":"2009","journal-title":"Heart"},{"issue":"10","key":"2019111809010126400_B70","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.111.075242","article-title":"Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven.","volume":"125","author":"Krishna","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"2019111809010126400_B71","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1538-7836.2005.01351.x","article-title":"Aspirin resistance: position paper of the Working Group on Aspirin Resistance.","volume":"3","author":"Michelson","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2019111809010126400_B72","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2012-02-406645","article-title":"Overcoming \u201caspirin resistance\u201d in MPN.","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111809010126400_B73","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2141.1997.362682.x","article-title":"Low-dose aspirin in polycythaemia vera: a pilot study.","volume":"97","author":"Gruppo Italiano Studio Policitemia Vera (GISP)","year":"1997","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111809010126400_B74","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.","volume":"115","author":"Dragani","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111809010126400_B75","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"2019111809010126400_B76","unstructured":"The European Agency for the Evaluation of Medicinal Products\n          Position paper on the regulatory requirements for the authorisation of low-dose modified release ASA formulations in the secondary prevention of cardiovascular events. EMEA\/CPMP\/EWP\/282\/02\/Final. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003340.pdf. Accessed January 30, 2013."},{"issue":"9573","key":"2019111809010126400_B77","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","article-title":"Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.","volume":"369","author":"Flossmann","year":"2007","journal-title":"Lancet"},{"issue":"9754","key":"2019111809010126400_B78","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"9759","key":"2019111809010126400_B79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"9826","key":"2019111809010126400_B80","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"2019111809010126400_B81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study.","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111809010126400_B82","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111809010126400_B83","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.","volume":"94","author":"Thun","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2019111809010126400_B84","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention.","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"2019111809010126400_B85","first-page":"4705","article-title":"Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.","volume":"60","author":"Chulada","year":"2000","journal-title":"Cancer Res"},{"issue":"10","key":"2019111809010126400_B86","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111809010126400_B87","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas.","volume":"348","author":"Baron","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111809010126400_B88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5085(03)00887-4","article-title":"Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.","volume":"125","author":"Benamouzig","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"2019111809010126400_B89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2007.10.014","article-title":"Aspirin and folic acid for the prevention of recurrent colorectal adenomas.","volume":"134","author":"Logan","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"2019111809010126400_B90","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","article-title":"A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.","volume":"131","author":"Baron","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"2019111809010126400_B91","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas.","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111809010126400_B92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","article-title":"Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.","volume":"108","author":"Patrono","year":"2001","journal-title":"J Clin Invest"},{"issue":"25","key":"2019111809010126400_B93","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"1-2","key":"2019111809010126400_B94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"issue":"3","key":"2019111809010126400_B95","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J Clin Invest"},{"issue":"18","key":"2019111809010126400_B96","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111809010126400_B97","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis.","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/10\/1701\/1364060\/1701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/10\/1701\/1364060\/1701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:06:40Z","timestamp":1574089600000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/10\/1701\/31210\/Platelet-activation-and-inhibition-in-polycythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,7]]},"references-count":97,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,3,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-10-429134","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,7]]}}}